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Edited by Lukas HuberAbstract Transglutaminase 2 (TG2) is a GTP-binding protein
with transglutaminase activity. Despite advances in the charac-
terization of TG2 functions and their impact on cellular
processes, the role of TG2 in Human chronic myelogenous
leukemia K562 cell line is still poorly understood. To understand
the biological signiﬁcance of TG2 during the diﬀerentiation of
K562 cells, we established and characterized K562 cells that
speciﬁcally express TG2. Non-transfected K562 cells showed the
increase of membrane-bound-TG2 level after 3 days in the
response to Hemin and all trans-retinoic acid (tRA), indicating
that membrane recruitment of TG2 is occurred during the
erythroid diﬀerentiation. However, membrane recruitment of
TG2 in TG2-transfected cells revealed within earlier time period,
compared with that in vector-transfected cells. The ability of
membrane-bound-TG2 to be photoaﬃnity-labeled with [a-
32P]GTP was also increased in TG2-transfected cells. TG2-
transfected cells activated Akt phosphorylation and inactivated
ERK1/2 phosphorylation, compared with vector-transfected
cells. Furthermore, phosphorylation of CREB, one of the Akt
substrates, was increased in TG2-transfected cells and this
phenomenon was conﬁrmed by RT-PCR analysis of several
marker genes related with erythroid lineage in the absence of
PI3K speciﬁc inhibitor, Wortmannin, indicating that PI3K/Akt
signaling pathway also involved in the diﬀerentiation of the cell.
Finally, as results of benzidine positive staining as well as
hemoglobinization analysis, overexpression of TG2 revealed
acceleration of the erythroid diﬀerentiation of K562 cells. Taken
together, there was no increased TG2 expression level in the
response of Hemin/tRA and delayed diﬀerentiation in vector
transfected cells than in TG2-transfected cells, suggesting that
suppression of TG2 expression may retard the erythroid
diﬀerentiation of K562 cells. Therefore, our study may give a
new insight for another aspect of the development of this disease.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transglutaminase 2 (TG2) is the most ubiquitously ex-
pressed member of the transglutaminase family of proteins [1].
TG2 exhibits at least two distinct enzymatic activities. One is a
Ca2þ-dependent transamidating activity that cross-links pro-
teins or incorporates polyamines into protein substrates [2,3]
and the other is GTPase (Gh) functioning as a GTP-binding
protein with transglutaminase activity and receptor signaling
function [4]. The most frequently reported cellular outcome
associated with aberrant TG2 transamidation activity has been
the induction of apoptosis [5–9]. However, several studies
provide evidences that TG2 has been implicated in regulating
cell diﬀerentiation [10–12] and cell survival [13,14]. Therefore,
TG2 is a multi-functional enzyme that can modulate several
biological events.
Cell diﬀerentiation is a complex process regulated by an
interplay among intrinsic cellular programs, cell–cell and cell–
substrate interactions, and a plethora of soluble extracellular
signaling molecules, including hormones, growth factors, cy-
tokines, trophic factors, and morphogens. All trans-retinoic
acid (tRA), the biologically active form of vitamin A, plays a
prominent role in regulating the transition from the prolifer-
ating precursor cell to the postmitotic diﬀerentiated cell, and
there are many examples in the literature of distinct cell types
whose diﬀerentiation is under the control of tRA [15–19].
However, no TG2 was induced following exposure to tRA in
human chronic myelogenous leukemia K562 cell line [20], al-
though it has been well established that tRA induced TG2
expression through the upregulation of the transcriptional
activities of its receptors [21].
K562 cell line was established from a patient with chronic
myeloid leukemia (CML) in terminal blast crisis [22] and this
cell line can be induced to undergo erythroid diﬀerentiation by
various compounds, including hemin [23] and megakaryocytic
diﬀerentiation by phorbol 12-myristate 13-acetate (PMA). It
has also been reported that retinoids (retinoic acid and syn-
thetic retinoids) dose-dependently enhance hemin-induced
erythroid diﬀerentiation of K562 cells [24].
Despite advances in the characterization of TG2 functions
and its impact on cellular processes, the role of TG2 during the
diﬀerentiation of K562 cells is still poorly understood. We
demonstrate the hypothesis that TG2 recruitment into mem-
brane is essential for the process of cellular diﬀerentiation of
K562 cells into erythroid lineage.blished by Elsevier B.V. All rights reserved.
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2.1. Cell culture
The human CML K562 cell line was used for stable transfection
with TG2 cDNA (gift from Mie-Jae Im, Chunbuk Univ. Korea)
using LipofectAMINE reagent following the manufacturer’s in-
structions. All cell lines were maintained using RPMI-1640 medium
supplemented with 10% fetal bovine serum (FBS), 100 lg/ml strep-
tomycin, and 100 U/ml penicillin G (Life Technologies) at 37 C in a
humidiﬁed 5% CO2 incubator. Transfected cells were then selected
and maintained by cell culture medium containing 600 lg/ml of
G418 sulfate.
Hemin and all tRA were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). To induce erythroid diﬀerentiation, K562 cells were
cultured for diﬀerent times in the presence of 2.5 nM hemin/1 lM tRA.
To induce megakaryocytic diﬀerentiation, the cells were treated with
phorbol 12-myristate 13-acetate (PMA, 10 nM).
2.2. Western blot analysis
K562 cells were lysed in RIPA buﬀer containing 150 mM NaCl,
20 mM Tris (pH 7.5), 1% Triton X-100, 2 mM EDTA, 10% (v/v)
glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM Na3VO4, 20 lg/ml
phenylmethylsulfonyl ﬂuoride, 10 lg/ml leupeptin, and 100 kallikrein
inhibitor units of aprotinin per ml. Cell lysates were clariﬁed by
centrifugation at 14 000 g for 10 min at 4 C. Proteins were sep-
arated on 10% polyacrylamide gels and then transferred to nitro-
cellulose (NC) membrane. After blocking non-speciﬁc bindings, the
NC membranes were incubated with speciﬁc antibodies, anti-phos-
pho-Akt (SantaCruz, USA), anti-phospho-ERK1/2 and anti-ERK1/2
(SantaCruz, USA), anti-phospho-p38 MAPK (Cell Signaling, USA),
anti-phospho-JNK (Cell Signaling, USA), anti-TG2 (CUB 7402,
Biomeda, USA), anti-phospho-CREB (Upstate, USA) and anti-
GAPDH (Chemicon, USA). After washing the membranes with PBS
three times, they were further incubated with horseradish peroxi-
dase-conjugated antibody. Immunoblots were revealed by autoradi-
ography using the enhanced chemiluminescence detection kit
(Amersham Biosciences, UK). Protein content of the samples was
determined by the Bradford method [25] using the Bio-Rad protein
assay reagent.
2.3. Preparation of membrane proteins
The cells were washed with PBS three times and lysed with buﬀer
containing 150 mM NaCl, 20 mM Tris (pH 7.5), 2 mM EDTA, 10%
(v/v) glycerol, 1 mM Na3VO4, 20 lg/ml phenylmethylsulfonyl ﬂuoride,
10 lg/ml leupeptin, and 100 kallikrein inhibitor units of aprotinin per
ml, and total membranes collected by centrifugation (13 000 rpm for 10
min). The membrane proteins were solubilized with RIPA buﬀer and
collected by centrifugation (13 000 rpm for 15 min).
2.4. Immunoprecipitation
Samples were pre-cleared with 50 ll of protein A-agarose beads at 4
C for 1 h and clariﬁed by centrifugation at 14 000 rpm for 10 min. The
precleared lysate was incubated with an antibody for 1 h, then 50 ll of
protein A-agarose beads was added and the mixture was further in-
cubated for 1 h. After extensive washing with RIPA buﬀer, the im-
munoprecipitated proteins eluted from beads were subjected to 10%
SDS–PAGE under reducing condition.
2.5. GTP binding assay
For photoaﬃnity labeling, membrane proteins (1 mg/ml) from each
cell line were incubated with 0.1 mCi of [a-32P]GTP in the presence of 2
mM MgCl2 at room temperature for 20 min, transferred to an ice-
bath, and cross-linked for 8 min by UV irradiation [26]. GTP-bound
TG2 was then immunoprecipitated with anti-TG2 antibody as de-
scribed above. The bound radiolabeled GTP was visualized by auto-
radiography, following SDS–PAGE (10% gel).
2.6. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from Hemin/tRA induced K562 cells using
the Trizol reagent (Invitrogen, Life Technologies, USA). One micro-
gram of RNA was subjected to reverse transcription with the random
nanomers and Takara RNA PCR kit (Takara Shuzo, Shiba, Japan)
according to the manufacturer’s protocol. The cDNA was ampliﬁed by
PCR with the following primers:glycophorin A (416 bp); 50-GTCAGCAATTG2TG2AG-
CATATCAGCA-30 (sense); 50-GATCACTTG2TCTCTG2CAT-
TTTCTAT (antisense)
c-globin (423 bp); 50-GGACAAGGCTACTATCACAA-30 (sense);
50-CAGTG2GTATCTG2GAGGACAG-30 (antisense)
CD36 (266 bp); 50-CTG2GCTG2TG2TTTG2GAGGTATTCT-30
(sense); 50-AGCGTCCTG2GGTTACATTTTCC-30 (antisense)
CD41b (379 bp); 50-AGGCCTCTG2TCCAGCTAC-30 (sense); 50-
GCCATTCCAGCCTCCGTG2-30 (antisense)
b-actin (247 bp); 50-CAAGAGATG2GCCACGGCTG2CT-30
(sense); 50-TCCTTCTG2CATCCTG2TCGGCA-30 (antisense)
The PCR products were separated on 2% agarose gel electrophoresis
containing ethidium bromide with 1 TAE buﬀer. After electropho-
resis, the intensity of the bands obtained from RT-PCR result was
estimated using TotalLab software of Frog Gel Image Analysis System
(CorebioSystem Co., Seoul, Korea).
2.7. Assay of erythroid diﬀerentiation
K562 cells were incubated with Hemin/tRA in various time points
indicated in the ﬁgure legends. Erythroid diﬀerentiation of K562 cells
was scored by benzidine staining according to the procedure reported
by Cooper et al. [27]. Benzidine positive cells (blue) were quantiﬁed
ðn ¼ 100Þ by light microscopy.
Hemoglobinization was determined by the visible absorbance spec-
trum of the supernatant at 414 nm [28].3. Results
3.1. Membrane recruitment of TG2 during the erythroid
diﬀerentiation of K562 cells
To investigate whether TG2 might be involved in erythroid
diﬀerentiation, the protein was separated into total, cytosol,
and membrane fraction. It is worth to note that no increase of
total TG2 level could be detected in the response to Hemin/
tRA, Hemin alone, and PMA (Fig. 1A–C, upper panel).
Membrane-bound TG2 appeared to be after 3 days in the
treatment of Hemin/tRA (Fig. 1A, lower panel), but there was
no increase of membrane bound TG2 in the response to Hemin
during the experimental time period (Fig. 1B, lower panel).
Furthermore, to investigate whether membrane bound TG2
could be increased during megakaryocytic diﬀerentiation of
K562 cells, the cells were treated with PMA (10 nM) for the
experimental time period. However, there was no increase of
membrane bound TG2 in the response to PMA (Fig. 1C, lower
panel), indicating that membrane recruitment of TG2 might be
unique phenomenon during the erythroid diﬀerentiation of the
cells induced by tRA.3.2. Enhancement of membrane recruitment and
GTP- photoaﬃnity by TG2 overexpression
To better understand the mechanism involved in the ery-
throid diﬀerentiation of K562 cell mediated by TG2, TG2
cDNA were stably transfected into K562 cells. Overexpres-
sion of TG2 was conﬁrmed by Western blot (Fig. 2A, upper
panel, time zero). TG2 transfected cells showed increase of
the membrane bound TG2 level than vector transfected cells
without Hemin/tRA (time zero) as well as after 2 days
treatment, however, the membrane bound TG2 level in
vector transfected cells was similar to that in TG2 trans-
fected cells after 4 days (Fig. 2A, lower panel). Cytosolic
TG2 level after fractionation was shown in Fig. 2A, middle
panel.
To determine the ability of membrane TG2 to bind GTP, [a-
32P]GTP-photoaﬃnity analysis was performed. Each cell lines
showed increase of GTP-photoaﬃnity of TG2 after 4 days in
Fig. 1. Increase of membrane recruitment of TG2 during the erythroid
diﬀerentiation of K562 cells. Each cell was incubated with Hemin/tRA,
Hemin alone, and PMA for the time courses described in the ﬁgure.
Proteins (50 lg) of the whole cell extracts, cytosol, and membrane
fraction were isolated and subjected to 10% SDS–PAGE as described
in Section 2. The expression levels of TG2 were determined via Wes-
tern blot analysis.
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aﬃnity of TG2 was measured in densitometry (Fig. 2C), vector
transfected cells after 4 days showed 2.3-fold increase than
those cells after 2 days. Furthermore, TG2 transfected cells
revealed 2.5- and 4.2-fold after 2 and 4 days, respectively,
compared to vector transfected cells after 2 days. Therefore,
these results indicated that the ability of membrane TG2 to
bind GTP was also increased during the erythroid diﬀerenti-
ation of K562 cell.
3.3. Activation of PI3K/Akt signaling pathway and inactivation
of ERK1/2 phosphorylation by TG2 overexpression
To investigate which signaling proteins might be involved in
erythroid diﬀerentiation by overexpression of TG2, WesternFig. 2. Overexpression of TG2 increases TG2 recruitment into mem-
brane and the ability of GTP-photoaﬃnity of TG2. (A) The cells were
transfected with pCDNA-TG2 cDNA. Expression of TG2 (approxi-
mately 87 kDa) was analyzed by Western blot using a speciﬁc antibody
to TG2. The cells were incubated with Hemin/tRA for the time period
indicated in the ﬁgure. Proteins (50 lg) of the whole cell extracts, cy-
tosol, and membrane fraction were isolated and subjected to 10%
SDS–PAGE as described in Section 2. The TG2 levels were determined
via Western blot analysis. (B) GTP binding activity of membrane
bound TG2 was determined using aﬃnity labeling with radioactive
GTP as described in Section 2. [a-32P]GTP-bound TG2 was then im-
munoprecipitated with anti-TG2 antibody. The bound radiolabeled
GTP was visualized by autoradiography, following SDS–PAGE (10%
gel). (C) Radiolabeled GTP was quantitated by densitometry. Values
are means for 3 independent experiments.blot was performed using speciﬁc antibodies that recognize
only the phosphorylated forms. TG2-transfected cells showed
activation of Akt phosphorylation in the response to Hemin/
tRA for 2 days (Fig. 3A). However, there was no activation of
p38 MAPK and JNK, indicating that overexpression of TG2
regulated PI3K/Akt signaling during the erythroid diﬀerenti-
ation. On the other hand, ERK1/2 phosphorylation was de-
creased in TG2 transfected cells. Previous investigations
[29,30] also showed that inhibition of ERK is involved in
erythroid diﬀerentiation.
To further investigate downstream activation of PI3K/Akt
signaling by overexpression of TG2, cyclic AMP-response el-
ement-binding protein (CREB) activation was measured. TG2
transfected cells showed increase of CREB phosphorylation
compared with vector transfected cells (Fig. 3B). However, no
increase of its phosphorylation could be detected in the pres-
ence of Wortmannin, which is a speciﬁc inhibitor of PI3K.
Erythroid diﬀerentiation of K562 cells was also conﬁrmed
by RT-PCR analysis with several diﬀerent erythroid lineage
marker genes. The mRNAs encoding c-globin and CD36 in
TG2 transfected cells clearly increased (Fig. 3C), but no
change in their mRNAs in the presence of the inhibitor was
observed.
3.4. Acceleration of erythroid diﬀerentiation of K562 cells by
TG2 overexpression
To conﬁrm biochemical studies above, benzidine staining on
phase contrast microscopy was performed. Benzidine positive
cells were clearly increased in TG2 transfected cells incubatedFig. 3. Overexpression of TG2 increases activation of PI3K/Akt sig-
naling pathway as well as the erythroid lineage marker genes. (A)
Proteins (25 lg) were subjected to 10% SDS–PAGE. Phospho-speciﬁc
antibody was used to measure the activation of Akt in the response of
Hemin/tRA for 2 days. The blots were stripped and then reprobed with
anti-p-ERK1/2, anti-p-p38 MAPK, and anti-p-JNK. (B) The cells were
incubated with Hemin/tRA for 2 days in the absence or in the presence
of Wortmannin (200 nM), PI3K speciﬁc inhibitor. Western blot
analysis was performed using anti-phospho-CREB antibody on 10%
SDS–PAGE. GAPDH indicated that equal amounts of proteins were
loaded in each lane (low panel). (C) One lg of total RNA from each
cell line was subjected to RT-PCR using primers speciﬁcally designed
for several erythroid lineage marker genes as described in Section 2. b-
Actin mRNA expression indicated that equal amounts of mRNA were
used for RT-PCR in each lane (lowest panel).
Fig. 5. Adrenergic receptor mediated signaling by TG2 involved in
the erythroid diﬀerentiation of K562 cells. Each cell line was incu-
bated with Epinephrine (105 M) for 2 days. One lg of total RNA
from each cell line was subjected to RT-PCR using primers speciﬁ-
cally designed for several erythroid lineage marker genes as described
in Section 2. CD41b is one of megakaryocytic diﬀerentiation marker
genes. b-Actin mRNA expression was also examined as a control
(lowest panel).
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(Fig. 4A). Indeed, when the cells were counted ðn ¼ 100Þ,
erythroid diﬀerentiated cells appeared to be 17% and 65% in
TG2 transfected cells, but 2% and 14% in vector transfected
cells after 2 and 4 days, respectively (Fig. 4B). Hemoglobini-
zation after treatment of Hemin/tRA for 2 days by the visible
absorbance spectrum of the supernatant at 414 nm was also
increased in TG2 transfected cells (Fig. 4C).
Because hemin is known to induce erythroid diﬀerentiation
of K562 cells reversibly [22], the K562 cells were treated with
Hemin for 4 days and further incubated without hemin for 4
days and then performed benzidine staining on phase contrast
microscopy. TG2 transfected cells showed longer diﬀerentia-
tion state after removal of hemin than vector transfected cells
(data not shown), indicating that overexpression of TG2 might
lead to irreversibility of hemin-induced diﬀerentiation.
3.5. Adrenergic receptor mediated signaling by overexpression
of TG2 involved in the erythroid diﬀerentiation of K562
cells
Because it is well known that TG2 is involved in adrenergic
receptor mediated signaling (4), the cells were treated with
Epinephrine (105 M) for 2 days and performed for RT-PCR.
The mRNAs encoding c-globin and CD36 clearly increased in
TG2 transfected cells, but CD41b, one of megakaryocytic
marker gene, had no change in its mRNA (Fig. 5), suggesting
that adrenergic receptor mediated signaling by overexpression
of TG2 might also be involved in the erythroid diﬀerentiation
of K562 cells.4. Discussion
TG2 is a soluble protein, mainly localized in the cytosolic
cell compartment, with a small fraction of the enzyme in the
membrane and extracellular matrix. The externalization of this
enzyme from cells is tightly regulated by a number of factors,
and is needed to stabilize the extracellular matrix, and to fa-
cilitate cell adhesion and motility [21,31]. Overexpression ofFig. 4. Acceleration of the erythroid diﬀerentiation of K562 cells by
TG2 overexpression. (A) The cells were incubated with Hemin/tRA for
2 and 4 days and performed benzidine staining as described in Section
2. (B) Benzidine positive cells were counted on phase contrast mi-
croscopy per 100 cells. (C) Hemoglobinization of these cells after
treatment of Hemin/tRA for 2 days was determined by the visible
absorbance spectrum of the supernatant as described in Section 2.TG2 involved in many patho-physiological conditions can be
associated with the translocation of TG2 to membrane com-
partment or in extracellular matrix [21]. However, in the
present study, membrane recruitment of TG2 plays an im-
portant role in erythroid diﬀerentiation of K562 cells and
overexpression of TG2 accelerates erythroid diﬀerentiation of
K562 cells via activation of PI3K/Akt signaling pathway.
It is well known that all tRA is the most powerful inducer
of TG2 expression via nuclear receptors [21,32,33]. However,
Western blot shown in Fig. 1 of the present paper demon-
strates that, after three days of treatment of Hemin/tRA, the
total TG2 level did not change in K562 cells, which is con-
sistent result with previous study [23]. Possible explanations
for this may be as follows; (1) the low expression level of
either RARs or RXRs resulting in not enough heterodi-
merization of these receptors to induce TG2 expression or (2)
these cell lines may have a diﬀerent promoter region of TG2,
which could not be induced in the response to tRA. In these
regards, the latter is more likely in K562 cells, because we
have found tRA-induced gene expression of ganglioside GD3
synthase that increases localization of TG2 into the mem-
brane during the erythroid diﬀerentiation of the cells in the
response to Hemin/tRA (Manuscript preparation). Grignani
et al. [34] reported that expression of either RAR alpha or
promyelocytic leukemia-speciﬁc PML-RAR alpha protein in
K562 cells resulted in a reduced expression of erythroid
diﬀerentiation markers and a reduced sensitivity to the ery-
throid diﬀerentiative action of heme. Unfortunately, the
functions of TG2 as well as tRA eﬀects on their study are
not clear. On the other hand, expression of the PML-RAR
alpha gene in myeloid U937 precursor cells resulted in the
ability of these cells to induce TG2 in response to tRA
during the granulocytic diﬀerentiation of these cells [35],
suggesting that stimulating eﬀect of retinoids on the expres-
sion of TG2 is diﬀerent depending on the cell type. In ad-
dition, there is no increased TG2 expression even if the cells
were treated with Hemin/tRA and delayed diﬀerentiation in
vector transfected cells than in TG2 transfected cells, sug-
gesting that suppression of TG2 expression may retard the
erythroid diﬀerentiation of K562 cells. Therefore, our study
may give a new insight for another aspect of the develop-
ment of this disease and provide a rationale for therapy with
agents that increase expression of TG2 that deserves further
investigation.
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lating diﬀerentiation in many cell types [36,37]. The protein
kinase Akt is one of the targets of PI3K and plays an im-
portant role in the regulation of cell death and survival
[38,39]. Our study also showed that overexpression of TG2
leads to phosphorylation of Akt in Ser-473 in the response
of Hemin/tRA as well as the acceleration of erythroid dif-
ferentiation of K562 cells, because inhibition of PI3K by its
speciﬁc inhibitor resulted in a block of diﬀerentiation,
according to biochemical criteria. In addition, the cyclic
AMP-response element-binding protein (CREB), one of Akt
substrates [40], is a transcription factor that is target of a
variety of signaling pathways mediating cell responses to
extracellular stimuli, involving proliferation, diﬀerentiation,
and adaptive responses of cell process [41,42]. Our result
that phosphorylation of CREB, one of the Akt substrates,
was increased in TG2-transfected cells supports previous
study that TG2 modulates the activation of CREB during
neuronal diﬀerentiation [43]. Indeed, transcription levels of
c-globin [44] and CD36 [45] genes are regulated by CREB
activation. Therefore, the coupling between cell diﬀerentia-
tion and survival elicited by TG2 overexpression may result
in allowing survival of the newly diﬀerentiated cell for a
limited time period.
GTP-bound TG2 participates in signaling pathways that
link cell surface receptors to intracellular eﬀectors because
PI3K can also be stimulated by G protein-coupled receptors
and integrin-dependent cell adhesion [46]. The most studied
example of this involved the upregulation of phospholipase
C activity by the a1-adrenergic receptor (AR) [4,47,48],
where it was shown that the a1-AR stimulated the GTP
binding activity of TG2. Moreover, it has been recently
shown that TG2 has an integrin-binding ability and involves
in adhesion and migration on ﬁbronectin [49]. The ability of
TG2 to transduce signals adds another dimension to its
functionality and may help explain how the same protein
can be linked to several, sometimes opposing, cellular re-
sponses. This point is exempliﬁed by the ﬁnding [50] that a
transamidation-defective form of TG2 as well as tRA in-
duced TG2 expression protected cells from apoptosis, indi-
cating that the GTP binding activity of TG2 likely mediated
the survival advantage. Therefore, these investigations sup-
port our study that GTP bound TG2 may display the un-
ique characteristic of being selectively recruited to the
membrane, especially during the erythroid diﬀerentiation of
K562 cells, which may facilitate receptor–receptor interac-
tions and enhance ligand-independent or dependent signaling
pathway.
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